Author:
Sailaja Inampudi,Kumar Baghel Manoj,Anand Shaker Ivvala
Abstract
One of the biggest challenges of the world in this 21st century is to cure HIV-AIDS. In Present scenario different antiviral drugs are available in the market to reduce the worse condition and manage improved survival rate. These drugs are manageable but their bioavailability, lower permeability and poor half life of the drugs have limitations. If the drug is preferred in higher dosage in AIDS patients, the drug leads to toxicity and adverse effects to patients and increase resistant against HIV & if the drug is preferred in lower dose along with nano carriers it will reach the target area for beneficial effect, therefore drugs Lacking of Knowledge in Potent Drug delivery systems is due to instability, chemical degradation and tissue barrier difficulties are reasons to reach drug target successfully. In this scenario Nanotechnology based antiretroviral drugs delivery holds drug and will provide to cure AIDS. Nanotechnology based deliver system Nanocarriers like Liposomes, dendrimers, Nanoparticles, Polymeric Micelles, Nanovesicles, Nanoemulsion provide the way to deliver drug to targeting tissue. Nanobased carriers revolutionized the field of Pharmaceutics and Pharmaco Kinetic’s in target drug delivery. The present study depicts nano based ARV drug provides increase efficiency with less adverse effects to control HIV. Like same way we can provide and increase nanobased drug delivery capacity to other available HIV drugs.
Reference80 articles.
1. WHO (Global Health Observatory Data Repository 2019). Available at: https://www.who.int/data/gho/data/themes/hiv-aids Accessed on 16 January 2021.
2. Wertheim, J. O., & Worobey, M. (2009). Dating the Age of the SIV Lineages That Gave Rise to HIV-1 and HIV-2. PLoS Computational Biology, 5(5), e1000377. doi: 10.1371/journal.pcbi.1000377
3. Pauwels, R., & De Clercq, E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association, 1996; 11(3), 211-221.
4. McGowan, I. Rectal microbicides: a new focus for HIV prevention. Sexually Transmitted Infections, 2008; 84(6), 413-417.
5. Boggiano, C., & Littman, D. R. HIV’s Vagina Travelogue. Immunity, 2007; 26(2), 145-147.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献